Skip to main content
. Author manuscript; available in PMC: 2009 Jul 1.
Published in final edited form as: Cell Death Differ. 2008 Oct 10;16(1):175–183. doi: 10.1038/cdd.2008.143

Figure 2. DT-EGF induces autophagy in glioblastoma cells.

Figure 2

Panel A, 2D-DIGE of lexatumumab or DT-EGF-treated U87MG cells compared with untreated controls. Lexatumumab treatment causes many changes to the proteome whereas DT-EGF treatment shows few changes. The boxed area identifies a post-translational change involving phosphorylation of eEF2 that is induced by DT-EGF treatment. Panel B, U87MG cells stably expressing GFP-LC3 were treated with DT-EGF or trehalose after transfection of siRNAs as indicated. Aggregation of LC3 was monitored by fluorescence microscopy after 24 hours and quantitated (Panel C) by counting the percentage of cells with > 10 GFP-labeled dots, data shown is the mean +/- SD from two experiments. Both DT-EGF and trehalose induce LC3 aggregation that is abolished by knockdown of autophagy regulators; only DT-EGF-induced aggregation is blocked by EGFR knockdown.